Lutetium Lu-177

ITM Isotope Technologies Munich and Alpha-9 Oncology have signed a supply agreement for Actinium-225, a rare medical radioisotope crucial for developing targeted cancer radiopharmaceuticals.

Novartis plans to invest $23 billion over five years to establish seven new facilities and expand three existing ones across the United States, enabling 100% end-to-end US production of key medicines.

Radiopharmaceuticals are emerging as a powerful precision medicine approach in oncology, with Novartis leading the market through FDA-approved therapies Lutathera and Pluvicto generating over $2.1 billion in 2024.

Amgen has initiated two pivotal Phase 3 trials of MariTide for obesity treatment, targeting both diabetic and non-diabetic populations with a three-tiered dosing strategy.

ITM Isotope Technologies Munich has reported positive Phase 3 data for their radiopharmaceutical therapy, positioning it as a potential competitor to Novartis' Lutathera in neuroendocrine tumors.